Pfizer Finalizes $10 Billion Metsera Acquisition, Plans Phase 3 Obesity Drug Trials
Pfizer has completed its $10 billion acquisition of Metsera and plans to launch 10 phase 3 trials of obesity drugs by year-end. This move positions Pfizer against Eli Lilly and Novo Nordisk in the growing cash-pay obesity drug market.
Insights:
Pfizer Inc. has successfully completed its $10 billion acquisition of Metsera, a prominent developer of obesity drugs, marking a significant strategic shift for the pharmaceutical giant. The acquisition, initially announced in September 2025, positions Pfizer to compete in the burgeoning obesity drug market, which is currently dominated by Eli Lilly and Company and Novo Nordisk A/S .
